We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

JAKK:NASDAQJAKKS Pacific, Inc. Analysis

Data as of 2026-05-19 - not real-time

$21.66

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

JAKKS Pacific trades at $21.66, sitting just below its 20‑day SMA of 22.37 but above the 50‑day SMA of 21.35, suggesting a marginal bullish bias despite a bearish MACD histogram and a neutral RSI of 46.8. The stock is navigating a high 30‑day volatility environment (42%) and a beta of 1.5**, indicating sensitivity to market swings, while volume has been on a downtrend, raising short‑term liquidity concerns. Recent earnings delivered a surprise loss of $0.17 versus the consensus loss of $0.36 (+52% surprise), with international sales jumping 38% even as North American revenue fell 16%, highlighting a shifting sales mix that could support future top‑line recovery.
From a valuation perspective, the company carries a trailing PE of 30.9 but a forward PE of 6.6 thanks to expected earnings upside, and analysts project a target price of $28.5 – roughly a 31% upside from current levels. However, the DCF fair value sits at only $16.36, the dividend yield is attractive at 4.6% but the payout ratio exceeds 140%, calling dividend sustainability into question. Combined with a modest ROE of 3.3% and a debt‑to‑equity ratio above 20, the stock appears fairly valued with a blend of growth and value characteristics, yet it carries elevated sector and market‑risk factors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Earnings beat with positive surprise
  • Bearish MACD and decreasing volume
  • Price near short‑term support at $20.20

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst target price implying ~31% upside
  • Strong international revenue growth
  • Forward PE compression to 6.6x

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Cyclical consumer sector exposure
  • High dividend payout ratio undermining sustainability
  • Elevated beta and volatility indicating market sensitivity

Key Metrics & Analysis

Financial Health

Revenue Growth-5.80%
Profit Margin1.41%
P/E Ratio30.9
ROE3.34%
ROA1.92%
Debt/Equity20.67
P/B Ratio1.0
Op. Cash Flow$32.0M
Free Cash Flow$13.4M

Technical Analysis

TrendBullish
RSI46.8
Support$20.20
Resistance$24.45
MA 20$22.37
MA 50$21.35
MA 200$18.82
MACDBearish
VolumeDecreasing
Fear & Greed Index89.61

Valuation

Fair Value$16.36
Target Price$28.50
Upside/Downside31.58%
GradeFair
TypeBlend
Dividend Yield4.61%

Risk Assessment

Beta1.52
Volatility42.10%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.